CD8A and chronic hepatitis C virus infection: Inhibition of HCV replication during DAA therapy leads to reversal of NK cells and phenotypic and functional shifts of CD4 and CD8 T cells typical of chronic hepatitis C. These changes during DAA therapy can trigger viral reactivation in patients with chronic hepatitis B and recurrence of HCC in some patients with previous successful cancer treatment.